US FDA approves Merck & Co's Dulera
This article was originally published in Scrip
Executive Summary
The US FDA has approved Merck & Co's asthma therapy Dulera as a new fixed-dose combination treatment for patients aged 12 years and over with persistent asthma. The product combines the inhaled corticosteroid (ICS) mometasone furoate with the long-acting beta2-agonist (LABA) formoterol fumarate in a single metered-dose inhaler, and is also under review in the EU.